This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Ford, A. C. et al. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 402, 1773–1785 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ray, K. Amitriptyline as second-line treatment for IBS in primary care settings. Nat Rev Gastroenterol Hepatol 21, 2 (2024). https://doi.org/10.1038/s41575-023-00873-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-023-00873-1